Spectrum Pharmaceuticals stock (US8485291018): what the Acrotech deal means for investors

Spectrum Pharmaceuticals was acquired by India-based Acrotech Biopharma in 2023, shifting the company’s focus and listing status. What remains of the former biotech story, and which milestones from the takeover still matter for investors today?

Spectrum Pharmaceuticals has undergone a fundamental transformation after its acquisition by Acrotech Biopharma, a subsidiary of Aurobindo Pharma, which closed in July 2023 according to a company announcement dated 07/31/2023 on the investor relations site of Spectrum Pharmaceuticals and related communications from Aurobindo Pharma as of 07/31/2023.

The transaction followed years of volatility around Spectrum Pharmaceuticals’ oncology pipeline and commercialization strategy, culminating in a cash deal that valued the former Nasdaq-listed company and transferred its assets to Acrotech’s oncology platform, as documented by an acquisition press release published on 04/25/2023 and closing confirmation on 07/31/2023 on Spectrum’s and Aurobindo Pharma’s investor pages.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Spectrum Pharmaceuticals
• Sector/industry: Biotechnology / oncology therapeutics
• Headquarters/country: Henderson, Nevada, United States
• Core markets: Oncology treatments primarily for the US and selected international markets
• Key revenue drivers: Commercial and pipeline oncology products historically focused on hematology and solid tumors
• Home exchange/listing venue: Previously Nasdaq (ticker: SPPI) prior to acquisition by Acrotech Biopharma
• Trading currency: US dollar (historical Nasdaq listing)

Spectrum Pharmaceuticals: core business model

Spectrum Pharmaceuticals historically operated as an oncology-focused biopharmaceutical company, aiming to develop and commercialize drugs for cancer patients, particularly in hematology and solid tumors, as described in its annual reports and corporate profile on the company’s website and investor relations materials published in 2022.

The company pursued a strategy that combined in-house development with in-licensing of late-stage assets, seeking to balance high-risk early research with nearer-term revenue opportunities from commercialized products in oncology, according to descriptions in Spectrum’s 2021 and 2022 filings and business updates released on its investor site during that period.

Prior to the acquisition, Spectrum Pharmaceuticals generated revenue from a portfolio that at different times included both legacy oncology brands and newer targeted therapies, while also investing in clinical development programs that required substantial R&D spending, as outlined in management’s discussion and analysis sections of its past Form 10-K filings with the US Securities and Exchange Commission.

Main revenue and product drivers for Spectrum Pharmaceuticals

Over the years leading up to the acquisition, Spectrum Pharmaceuticals relied on a mix of oncology products and late-stage candidates as key revenue and value drivers, with commercial sales and potential future approvals providing the financial foundation for the business, according to historical earnings releases and pipeline overviews on the company’s website.

The strategic rationale for the sale to Acrotech Biopharma emphasized the potential to integrate Spectrum’s oncology assets into a broader oncology franchise, leveraging Acrotech’s and Aurobindo Pharma’s existing commercialization infrastructure and portfolio, as described in the merger announcement issued on 04/25/2023 on Spectrum’s investor relations page and in related commentary from Aurobindo Pharma on the same date.

At the same time, the company’s financial profile before the acquisition reflected the typical risk profile of small and mid-cap biotech issuers, with fluctuating revenues and ongoing net losses linked to R&D and commercialization investments, a pattern that management discussed in prior quarterly reports and earnings calls referenced in the 2022 annual report.

Industry trends and competitive position

The oncology therapeutics market has remained one of the fastest-growing segments in global pharmaceuticals, driven by advances in targeted therapies and immuno-oncology as documented in industry analyses from organizations such as IQVIA and EvaluatePharma released in 2023 and 2024.

For a company like Spectrum Pharmaceuticals, competition has historically been intense, with numerous large multinational pharma companies and specialized biotechs pursuing overlapping indications and mechanisms of action, a dynamic that management often highlighted as a key risk factor in prior SEC filings and risk disclosures in the 2021 and 2022 Form 10-K documents.

The acquisition by Acrotech Biopharma positioned Spectrum’s assets within a broader portfolio strategy, where scale and diversification across different oncology products can help mitigate some individual pipeline risks, according to transaction rationale statements in the 04/25/2023 acquisition press release and Aurobindo Pharma’s investor communications on that date.

Conclusion

The story of Spectrum Pharmaceuticals has effectively transitioned from that of an independent Nasdaq-listed oncology biotech to a component of Acrotech Biopharma’s broader oncology platform, following the completion of the acquisition in mid-2023 and subsequent integration work referenced in transaction updates at that time. For investors, the key milestones now lie in understanding how Spectrum’s former assets contribute to Acrotech’s and Aurobindo Pharma’s overall oncology strategy and financial performance. The case also illustrates the broader consolidation trend in the biotech sector, where smaller oncology players often ultimately combine with larger platforms after years of clinical and commercial risk-taking.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.